MDLinxThese Lymphoma Subtypes are Different Diseases, Despite Being Grouped Together

Virally associated brain lymphomas once grouped together are actually distinct diseases with opposite immune profiles. Largest-ever multiomic analysis of 72 PCNSL patients reveals AR-PCNSL has genetically-driven immune suppression while CNS-PTLD has intact immunity blocked by checkpoint proteins—fundamentally different biology requiring different treatments.

🧬 CLINICAL CONSIDERATIONS

• AR-PCNSL shows 87.5% reduction in standard PCNSL mutations (MYD88, CD79B, PIM1, CARD11 present in only 29% vs. 87.5% in EBV-negative cases), suggesting viral oncogenesis replaces typical mutation-driven pathways
• CNS-PTLD retains functional antigen presentation and immune activation despite EBV infection, creating immune-engaged tumor microenvironment vulnerable to checkpoint modulation rather than immune restoration
• AR-PCNSL patients have genetically-impaired antigen presentation via NLRC5/Notch mutations associated with poor survival, explaining why standard immunotherapy approaches may fail in this population
• High tumor mutational burden in AR-PCNSL suggests neoantigen-directed approaches could work if antigen presentation pathways can be restored, fundamentally different strategy than CNS-PTLD

💊 PRACTICE APPLICATIONS

• Stratify EBV-positive PCNSL patients into AR-PCNSL vs. CNS-PTLD subtypes before selecting immunotherapy approaches
• Consider checkpoint inhibitors preferentially for CNS-PTLD patients with intact immune function rather than applying uniformly across EBV+ cases
• Recognize that AR-PCNSL’s genetic immune suppression may require immune restoration strategies beyond standard checkpoint blockade
• Avoid grouping virally-associated PCNSL as single entity when discussing prognosis or treatment options with patients

More in Neuro-Oncology